1. Home
  2. Sistema de Salut de Catalunya
  3. Hospital General de Granollers - HG
  4. Articles científics - HG
  5. View Item

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

To access the full text documents, please follow this link: http://hdl.handle.net/11351/14233

Author

Castaño-Díez, Sandra

Gómez-Hernando, Marta

Zugasti, Inés

Jimenez-Vicente, Carlos

Vela, Dolors

Álamo , José Ramón

Lopez-Guerra, Monica

Other authors

[Castaño-Díez S] Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Universitat Barcelona, Barcelona, Spain. [Álamo JR, Gómez-Hernando M] Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain. [López-Guerra M] Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. [Zugasti I, Jiménez-Vicente C] Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain. [Vela D] Hematology Department, Hospital General de Granollers, Granollers, Spain

Hospital General de Granollers

Publication date

2026-02-10T11:40:27Z

2026-02-10T11:40:27Z

2025-02-06



Share

Abstract

Acute myeloid leukemia; Chronic myelomonocytic leukemia; ICC classification

Leucèmia mieloide aguda; Leucèmia mielomonocítica crònica; Classificació de la CCI

Leucemia mieloide aguda; Leucemia mielomonocítica crónica; Clasificación ICC

The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.

Document Type

Article

Published version

Language

English

Subjects and keywords

Leucèmia mieloide aguda; Leucèmia mieloide crònica; Nosologia; DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute; DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myelomonocytic, Chronic; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Errors; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielomonocítica crónica; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::errores diagnósticos

Publisher

Oxford University Press

Related items

The Oncologist;30(2)

https://doi.org/10.1093/oncolo/oyae246

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)

Articles científics - HG [170]